Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Align Technology Inc is a medical devices business based in the US. Align Technology shares (ALGN) are listed on the NASDAQ and all prices are listed in US Dollars. Align Technology employs 20,395 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$727.11|
|52-week range||$297.44 - $735.17|
|50-day moving average||$702.73|
|200-day moving average||$613.64|
|Wall St. target price||$745.36|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$8.77|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-09-16)||-0.16%|
|1 month (2021-08-24)||2.00%|
|3 months (2021-06-24)||17.77%|
|6 months (2021-03-24)||43.65%|
|1 year (2020-09-24)||133.14%|
|2 years (2019-09-24)||297.22%|
|3 years (2018-09-24)||86.94%|
|5 years (2016-09-23)||672.45%|
Valuing Align Technology stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Align Technology's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Align Technology's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 82x. In other words, Align Technology shares trade at around 82x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Align Technology's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.7789. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Align Technology's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Align Technology's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $985.4 million.
The EBITDA is a measure of a Align Technology's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$3.5 billion|
|Operating margin TTM||25.46%|
|Gross profit TTM||$1.8 billion|
|Return on assets TTM||11.74%|
|Return on equity TTM||22.42%|
|Market capitalisation||$56.8 billion|
TTM: trailing 12 months
There are currently 1.7 million Align Technology shares held short by investors – that's known as Align Technology's "short interest". This figure is 3.2% up from 1.7 million last month.
There are a few different ways that this level of interest in shorting Align Technology shares can be evaluated.
Align Technology's "short interest ratio" (SIR) is the quantity of Align Technology shares currently shorted divided by the average quantity of Align Technology shares traded daily (recently around 492354.62427746). Align Technology's SIR currently stands at 3.46. In other words for every 100,000 Align Technology shares traded daily on the market, roughly 3460 shares are currently held short.
However Align Technology's short interest can also be evaluated against the total number of Align Technology shares, or, against the total number of tradable Align Technology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Align Technology's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Align Technology shares in existence, roughly 20 shares are currently held short) or 0.0234% of the tradable shares (for every 100,000 tradable Align Technology shares, roughly 23 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Align Technology.
Find out more about how you can short Align Technology stock.
We're not expecting Align Technology to pay a dividend over the next 12 months.
Over the last 12 months, Align Technology's shares have ranged in value from as little as $297.44 up to $735.17. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Align Technology's is 1.6845. This would suggest that Align Technology's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Align Technology, Inc. , a medical device company, designs, manufactures, and markets Invisalign clear aligners and iTero intraoral scanners and services for orthodontists and general practitioner dentists, and restorative and aesthetic dentistry. It operates in two segments, Clear Aligner; and Scanners and Services. The Clear Aligner segment consists of comprehensive products, including Invisalign comprehensive treatment that addresses the orthodontic needs of teenage patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of seven and ten years, which is a mixture of primary/baby and permanent teeth. This segment's non-comprehensive products comprise Invisalign moderate, lite and express packages, and Invisalign go; and non-case products include retention products, Invisalign training fees, and sales of ancillary products, such as cleaning material, and adjusting tools used by dental professionals during the course of treatment. The Scanners and Services segment offers iTero scanner, a single hardware platform with software options for restorative or orthodontic procedures; restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons; and software for orthodontists for digital records storage, orthodontic diagnosis, and for the fabrication of printed models and retainers. This segment also provides computer-aided design and computer-aided manufacturing services; ancillary products, such as disposable sleeves for the wand; iTero model and dies; third party scanners and digital scans; Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; and TimeLapse technology, which allows doctors or practitioners to compare a patient's historic 3D scans to the present-day scan.
Everything we know about the Enfusion IPO, plus information on how to buy in.
Everything we know about the Intuity Medical IPO, plus information on how to buy in.
Everything we know about the Pyxis Oncology IPO, plus information on how to buy in.
Everything we know about the AEON Biopharma IPO, plus information on how to buy in.
Everything we know about the IHS Holding Ltd IPO, plus information on how to buy in.
Everything we know about the BT Brands IPO, plus information on how to buy in.
Everything we know about the Immix IPO, plus information on how to buy in.
Everything we know about the Keter Group SA IPO, plus information on how to buy in.
Everything we know about the Theseus Pharmaceuticals IPO, plus information on how to buy in.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq on Sep. 20, 2021
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.